2,4-dimethoxy-6-methylsulfanyl-pyrimidine | 89943-44-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2,4-dimethoxy-6-methylsulfanyl-pyrimidine
• 英文别名: 2,4-Dimethoxy-6-methylmercapto-pyrimidin；2,4-Dimethoxy-6-methylsulfanylpyrimidine
• CAS: 89943-44-2
• 化学式: C₇H₁₀N₂O₂S
• 分子量: 186.235
• InChiKey: NRCCOQFBOKPWFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  69.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,4-dimethoxy-6-methylsulfanyl-pyrimidine 在 盐酸 、 甲酸 、 双氧水 、 溶剂黄146 作用下， 生成 Uracil-6-methylsulfon
  参考文献：
  名称：

  Potential Metabolic Antagonists of Orotic Acid: 6-Uracilsulfonamide and 6-Uracil Methyl Sulfone¹

  摘要：

  DOI：

  10.1021/ja01652a056
• 作为产物：
  描述：

  6-氯-2,4-甲氧基嘧啶 在 sodium hydroxide 、 硫化氢 、 sodium ethanolate 作用下， 生成 2,4-dimethoxy-6-methylsulfanyl-pyrimidine
  参考文献：
  名称：

  Potential Metabolic Antagonists of Orotic Acid: 6-Uracilsulfonamide and 6-Uracil Methyl Sulfone¹

  摘要：

  DOI：

  10.1021/ja01652a056

文献信息

• TETRACYCLIC INHIBITORS OF JANUS KINASES
  申请人：Rodgers James D.

  公开号：US20090215766A1

  公开（公告）日：2009-08-27

  The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

  本发明提供了一种可以调节Janus激酶活性的化合物，这些化合物可用于治疗与Janus激酶活性相关的疾病，例如免疫相关疾病和癌症。
• GYRASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170037059A1

  公开（公告）日：2017-02-09

  Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula (I), are disclosed: Formula (I), wherein Y is N or CH; Z is N or CR 5 ; R 5 is H, a substituted or unsubstituted hydrocarbyl residue (1-3C) containing 0-2 heteroatoms selected from O, S and N, or is an inorganic residue; L is O, S, NR 7 , or CR 8 R 9 ; R 7 is H or C 1-3 alkyl; R 8 and R 9 are each independently H or C 1-3 alkyl; R 2 is H, a hydrocarbyl residue (1-40C) containing 0-10 heteroatoms selected from O, S and N optionally substituted with an inorganic residue; R 4 is H, an inorganic residue, or a hydrocarbyl residue (1-30C) containing 0-12 heteroatoms selected from O, S and N and containing 0-10 inorganic residues, wherein R 5 and R 4 together may join to form a fused ring; and R 6 is selected from the group consisting of H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, halo C 1-5 alkyl, halo C 2-5 alkenyl, halo C 2-5 alkynyl, C 1-5 hydroxyalkyl, C 1-5 alkyl chloride, C 2-5 alkenyl chloride, and C 2-5 alkynyl chloride; or a pharmaceutically-acceptable salt, ester, or prodrug thereof.
• US9556201B2
  申请人：——

  公开号：US9556201B2

  公开（公告）日：2017-01-31
• Potential Metabolic Antagonists of Orotic Acid: 6-Uracilsulfonamide and 6-Uracil Methyl Sulfone¹
  作者：Sheldon B. Greenbaum

  DOI：10.1021/ja01652a056

  日期：1954.12